Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (February 2024)
54 slides from Genprex's investor presentation, February 2024
Slide 1: Pioneering Gene Therapies for Patients in Need
Pioneering Gene Therapies for Patients in Need February 2024 w w w. g e n p r e x . c o m | N A S D A Q : G N P X
Slide 2: Forward-Looking Statements
Forward-Looking w w w. g e n p re x . c o m Statements Statements contained in this presentation regarding matters that are not historical facts candidates, and whether patents will ever be issued under patent applications filed by us are “forward-looking statements” within the meaning of the Privat
Slide 3: Our Mission
Our Mission Advancing novel gene therapies for patients afflicted with cancer or diabetes.
Slide 4: Program Highlights
Program Highlights ONCOLOGY DIABETES Non-viral gene therapy platform Addressing both Type 1 and Type 2 diabetes with AAV gene therapy Novel approach using systemic gene therapy to replace tumor suppressor genes for cancer in Novel infusion process delivers genes to pancreas humans Demonstrated abili
Slide 5: Research and Development Pipeline
Research and Development Pipeline Delivery Drug Clinical Trial Regulatory Clinical Clinical Clinical Indication Discovery Preclinical IND-Enabling System Candidate Program Name Designation Phase 1 Phase 2 Phase 3 Fast Track REQORSA® IMMUNOGENE THERAPY NSCLC REQORSA® + Tagrisso Designation (ONC-003)
Slide 6: Oncology
ONCOLOGY R EPR OG R AM M I NG T HE COU R S E OF CANCER w w w. g e n p re x . c o m
Slide 7: Tumor Suppressor Genes Deleted During Cancer Development
Tumor Suppressor Genes Deleted During Cancer Development Why TUSC2? Tumor suppressor genes are deleted early during cancer development 82% of all non-small cell lung cancers and 100% of all small-cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein Loss or reduction of TUSC2
Slide 8: Reqorsa Targets Cancer At Its Core
Reqorsa® Targets Cancer Multiple anti-cancer At Its Core mechanisms of action. 1 2 3 Controls Cell Signaling Stimulates Apoptotic Pathways Modulates Immune Response Pan-kinase inhibition Leads to programmed Promotes immune decreases cancer cell cancer cell death activity against cancer proliferation
Slide 9: Our Cancer Treatment Approach
Our Cancer Treatment Approach Tumor Suppressor Gene in a DNA Plasmid Tumor suppressor genes are 1 We have rights to tumor suppressor genes that may have cancer-fighting functions. These genes are deleted early during cancer expressed in a DNA plasmid. development. Non-Viral Lipid Nanoparticles Our m
Slide 10: Novel Platform to Treat Cancer
Novel Platform to Systemic Gene Therapy Platform: ONCOPREX® Nanoparticle Delivery System Treat Cancer Genes Allows for delivery of TUSC2 and NPRL2 genes and potentially a variety of other genes Synergies Can be used in combination with other cancer therapies such as Tagrisso®, Keytruda® and Tecentri
Slide 11: Oncoprex Nanoparticle Delivery System
Oncoprex® Nanoparticle Non-viral, positively-charged lipid nanoparticle Delivery System (LNP) is systemically delivered. Cationic lipid nanoparticle carries drug to tumors.
Slide 12: Selective Uptake of Reqorsa
Selective Uptake REQORSA Targets Cancer Cells of Reqorsa® Pretreatment Biopsies Posttreatment Biopsies REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing its uptake by normal tissue. Patient 1 (.02 mg/kg) Tumor biopsy studies show that, in three patients, the
Slide 13: Lung Cancer: By the Numbers
Lung Cancer: By the Numbers 127K 2M+ $48B 238K 26.6% U.S. Annual Global Lung Global U.S. Lung U.S. Average Mortality Cancer Incidence Market Cancer Incidence Lung Cancer Survival More than 127,000 More than two million Global market is projected More than 238,000 new Rate deaths new cases per year t
Slide 14: Drug resistance to Tagrisso, Keytruda and Tecentriq is inevitable
For most patients, drug resistance to Tagrisso®, Keytruda® and Tecentriq® is inevitable.1,2,3 Our approach is designed to address drug resistance. REQORSA Immunogene Therapy may be complementary with targeted drugs and immunotherapies. REQORSA’s multimodal activity may block emerging bypass pathways
Slide 15: AACR 21: Reqorsa + Tagrisso Reduce Tumor Growth
AACR 21: Reqorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors TUSC2 Osimertinib TUSC2 TUSC2 21 Days Survival & tumor growth 12/16 01/07/20 01/10 01/13 Cell inoculation Enhanced Anti-Tumor Activity Osimertinib+TUSC2 combination on Osimertinib+TUSC2 combination on H1975-OsiR tumors in
Slide 16: Reqorsa + Tagrisso Trial Design for NSCLC
o FDA Fast Track Designation o Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso® o ~15-20 U.S. sites o ~158 patients o Phase 1 Dose Escalation: 12 patients (completed) o Phase 2a Expansion: ~66 patients in 2 cohorts (opening for enrollment in Jan. 2024) o Phase 2b: ~
Slide 17: Phase 1 Dose Escalation
Phase 1 Dose Escalation Excellent safety profile and efficacy in relapsed patients. Reqorsa® in combination with AstraZeneca’s Tagrisso® for NSCLC REQORSA was generally well tolerated with no DLTs. 3/12 patients progressing on Tagrisso containing regimens had prolonged PFS on REQORSA + Tagrisso comb
Slide 18: Reqorsa with Immunotherapies
Reqorsa® with Immunotherapies Survival on Lung Metastasis Model Non-Treated REQORSA Treated Control 100 PD1+CTLA4 REQORSA Percent Survival REQORSA+PD1 REQORSA+PD1+CTLA4 50 0 10 15 20 25 Days REQORSA+anti-PD1 exhibit REQORSA+anti-PD1 combination greater anti-tumor activity than significantly prolonge
Slide 19: Reqorsa + Keytruda Significantly Reduced Tumor Growth
Reqorsa® + Keytruda® REQORSA increases immune response against lung cancer xenografts Significantly Reduced Tumor Growth REQORSA + Keytruda® Pembrolizumab is the generic name of Keytruda. Pembrolizumab is the generic name of Keytruda. The independent immunologic effects of REQORSA and Keytruda marke
Slide 20: AACR 21: Reqorsa May Enhance First-Line Standard of Care
AACR 21: Reqorsa® May Enhance First-Line Standard of Care Reqorsa® + Keytruda® + Chemo Triple treatment on A549 lung met in humanized mice Tumor intensity (Wk4) post treatment Tumor intensity (total flux [p/s]) 2x109 REQORSA enhances the efficacy of 1.5x109 chemo-immunotherapy on KRAS-LKB1 ** 1x109
Slide 21: Reqorsa + Keytruda Trial Design for NSCLC
o FDA Fast Track Designation o Patients with advanced NSCLC whose disease progressed after treatment with Keytruda® o ~10 U.S. sites o ~180 patients o Phase 1 Dose Escalation: Up to 18 patients o Phase 2a Expansion: 36 patients o Phase 2b Randomized: 126 patients o Phase 2b interim analysis at 50 ev
Slide 22: Reqorsa in Small Cell Lung Cancer
Reqorsa® in Small Cell Lung Cancer Targeting Small Cell Lung Cancer (in addition to NSCLC) allows Genprex® to address virtually the entire lung cancer market. Small Cell Lung Cancer: Consistently has low TUSC2 protein levels Documented to often have deletion of at least one TUSC2 gene allele. Small
Slide 23: SCLCs Express Low Levels Of TUSC2 Protein
SCLCs Express Low Levels Of TUSC2 Protein IHC analysis of tumor specimens Since all SCLCs have reduced or no TUSC2 41% of SCLC have no TUSC2 protein expression protein expression, re-expressing TUSC2 100% of SCLC have reduced or no TUSC2 protein protein may lead to clinical efficacy. expression
Slide 24: Atezolizumab (Tecentriq) SCLC Approval Trial
Atezolizumab (Tecentriq®) SCLC Approval Trial IMpower133 Study Adding Tecentriq to standard therapy improves survival in SCLC and establishes a new standard therapy for ES-SCLC. Untreated, extensive stage SCLC Carboplatin & etoposide chemotherapy + atezolizumab or placebo • 4 cycles, then atezolizum
Slide 25: Atezolizumab Maintenance Therapy
Atezolizumab Maintenance Therapy Once patients begin maintenance therapy with Tecentriq, Progression Free Survival is very short (2.6 mos). Atezolizumab vs placebo • All CR, PR, and SD patients received maintenance therapy • Endpoints measured from the start of maintenance therapy PFS 2.6 vs 1.8 mos
Slide 26: Reqorsa + Tecentriq Trial Design for SCLC
o Fast Track Designation and Orphan Drug Designation o Patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq® and chemotherapy o ~10 U.S. sites o ~62 patients o Phase 1 Dose Escalation: Up to 12 patients (open for enrollment in Jan. 2024) o Phase 2: ~50 patients Reqor
Slide 27: AACR 23: NPRL2 Induces Anti-tumor Activity in NSCLC
AACR 23: NPRL2 Induces Anti-tumor Activity in NSCLC Further Evidence of Oncoprex® Delivery System as a Platform for Treatment Using Tumor Suppressor Genes Study investigated the antitumor responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC in a humanized mouse model Humaniz
Slide 28: Diabetes
2 DIABETES www.genprex.com
Slide 29: Diabetes: By the Numbers
Diabetes: By the Numbers 37M 537M $966B $92B $24B Diabetes U.S.1 Diabetes Global2 Global Diabetes T2D Global Market T1D Global Market Prevalence Prevalence Expenditures (6.7% CAGR3) (17.2% CAGR4) 96M U.S. adults (38% Expected to rise to 643M by 316% increase in global $57B expected U.S. $20.3B expec
Slide 30: Diabetes can cause serious complications
Diabetes can cause serious complications. In 2021, there was approximately 1 death every 5 seconds caused by diabetes worldwide.
Slide 31: Diabetes Causes Serious Complications
Diabetes Causes Serious Complications Heart Disease Vision Loss (Diabetic Retinopathy) Leading cause of death for men and women in U.S. Diabetic retinopathy affects almost 1/3 of adults over 40 years old. Diabetics are 2x as likely to have heart disease or a stroke. Diabetes is leading cause of new
Slide 32: Diabetic Patients Are In Need of Advanced Therapy
Diabetic Patients Are In Potential for disease modification Need of Advanced Therapy for long-term effectiveness. Patients suffer compromised quality of life Despite certain advancements in treatment, quality 1922 Islets of Langerhans Recombinant produce insulin and DNA techniques of life remains hi
Slide 33: Novel Gene Therapy Diabetes Program
Novel Gene Therapy Collaboration with University of Pittsburgh Diabetes Program intends to address both T1D and T2D. 37.3M or 11.3% of Americans Have Diabetes1 Type 1 Diabetes (5-10%) Type 2 Diabetes (90-95%) An auto-immune condition where the body's Inability of the pancreas to produce enough immun
Slide 34: GPX-002 Replenishes Levels Of Insulin
GPX-002 Replenishes Reprograms and restores Levels Of Insulin cell function in T1D. Delivers Genes to the Pancreas A novel infusion process uses an AAV vector to deliver the Pdx1 + MafA (PM) genes to the pancreas. Reprograms Alpha Cells GPX-002 transforms alpha cells in the pancreas into functional
Slide 35: Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model
Reversed Drug-Induced Diabetes in T1D Toxin-Induced Mouse Model 600 Blood glucose (mg/dl) 400 AAV8-GFP 200 AAV8-PM 0 0 7 14 21 28 35 alloxan AAV-8 injection GFP = Green Fluorescent Protein (fluorescent marker) | PM = Pdx1 + MafA Reprogramed alpha cells into beta-like cells that appropriately produce
Slide 36: Restored Blood Glucose in T1D Autoimmune Mouse Model
Restored Blood Glucose in T1D Autoimmune Mouse Model for Four Months The duration of restored blood 600 glucose levels in mice could Blood glucose (mg/dl) potentially translate to decades in humans. 400 AAV8-GFP One week in a mouse tends to 200 correlate to about one year in humans. AAV8-PM 0 -2 0 2
Slide 37: Functional Insulin Expressing Cells from Alpha Cells in Human Islets
Induced Generation of Functional Insulin Expressing Cells from Alpha Cells in Human Islets Provides a potential basis for further investigation in human Type 1 diabetes Human islets treated with streptozotocin 1.0 600 to destroy beta-cells, then treated with either AAV-PM or AAV-GFP Graft beta cell
Slide 38: Insulin/Carb Ratio in NHP Model of T1D
NHP 1 Insulin / Carb Viral Infusion 1.50 Insulin/Carb Ratio 1.00 Non-Human 0.50 Primate 0.00 2 6 10 14 18 22 26 30 34 38 42 46 50 54 58 62 66 70 74 78 Model of T1D STZ -34 -30 -26 -22 -18 -14 -10 -6 -2 Reduced Insulin Requirements NHP 2 Insulin / Carb Viral Infusion 2.00 Insulin/Carb Ratio 1.50 1.00
Slide 39: ATTD 23: Statistically Significant Decreases In Insulin Requirements in NHPs
ATTD 23: Statistically Significant Decreases In Insulin Requirements in NHPs Following the pancreatic intraductal infusion of the AAV engineered NHP2 Recent Glucose Average Insulin Requirements Tolerance Test construct, the eight NHPs had: Decreased insulin requirements (p<0.001) Increased c-peptide
Slide 40: NHP2 Three-Month Glucose Tolerance Test
NHP2 Three-Month Glucose Tolerance Test 500 Pre Gene Therapy Post Gene Therapy (3 months) Normal NHP 400 Glucose (mg/dL) 300 200 100 0 0 20 40 60 Time (min)
Slide 41: IHC In a Normal NHP
IHC In a Normal NHP INSULIN GLUCAGON DAPI
Slide 42: IHC Eight Weeks After Gene Therapy
IHC Eight Weeks After Gene Therapy Need at least 20% of normal beta cell mass to maintain normoglycemia DAPI INSULIN GLUCAGON Diabetic NHP Without Gene Therapy Diabetic NHP After Gene Therapy
Slide 43: Corporate
Q CORPORATE www.genprex.com
Slide 44: Our Team: Company Management
Our Team: Company Management Rodney Varner, JD Ryan Confer, MS Mark S. Berger, MD Thomas Gallagher, JD David Schloss, JD Suzanne Thornton-Jones, PhD Chairman, President & Chief Financial Officer Senior Vice President, Senior Vice President, Chief Medical Officer Senior Vice President, Chief Executiv
Slide 45: Our Team: Scientific Advisory Board
Our Team: Scientific Advisory Board Jack A. Roth Tony S. K. Mok Pasi Antero Jänne George Simon George K. Gittes MD, FACS, Chairman MD, FRCP(C), FHKCP, FHKAM MD, PhD MD MD Professor and Bud Johnson Professor and Chair of Clinical Professor of Medicine, Chair, Department of Medical Chief of Pediatric
Slide 46: Our Team: Clinical Advisory Board
Our Team: Clinical Advisory Board Michael Morse Andrew Becker Col. George Peoples MD, MHS, FACP MD, PhD MD, FACS Professor of Medicine, President and Founder, Chief Executive Officer of Division of Medical Oncology Becker Pharmaceutical Cancer Insight, LLC, a in the Department of Surgery Consulting
Slide 47: Our Team: Board of Directors
Our Team: Board of Directors Rodney Varner, JD Jose A. Moreno Toscano William R. Wilson, Jr. Brent Longnecker James E. Rothman, PhD Chairman of the Board Board Director Board Director Board Director Strategic Advisor to the Board 30+ years of expertise in Chief Executive Officer, LFB Chief Executive
Slide 48: Achievements & Upcoming Milestones
Achievements & Upcoming Milestones GPX-002 & Corporate GPX-003 Present full data from Complete Open for Report data from Expand global IP Phase 1 portion of the enrollment for enrollment in Phase ongoing preclinical portfolio (Ongoing) trial at the 2023 AACR- Phase 1 Dose 1 Dose Escalation studies i
Slide 49: We believe in a future of transformational patient care
We believe in a future of transformational patient care. 21st Century Large Combination Three FDA Exploring New Gene Markets & Trials with Top Fast Track Indications & Therapies Unmet Need Selling Drugs Designations Partnerships
Slide 50: NASDAQ: GNPX
NASDAQ: GNPX | (877) 774 - GNPX | investors@genprex.com | www.genprex.com
Slide 51: Research References
Research References Slide 12 Slide 29 1. Centers for Disease Control: https://bit.ly/3Vk2gmL 1. Selective and Preferential Cancer Cell Uptake and Anti-Cancer Activity In 2. International Diabetes Federation: https://bit.ly/3SXWohu Advanced Lung Cancer Patients. Lu et al. PLoS1 (2012). 3. Research an
Slide 52: Research References
Research References Slide 32 Slide 57 (Appendix) 1. American Diabetes Association: https://diabetes.org/blog/history-wonderful- 1. Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles thing-we-call-insulin Mediating Functional Gene Transfer in Humans Lu C, Stewart DJ, Lee JJ
Slide 53: Appendix
a) APPENDIX www.genprex.com
Slide 54: ONC-001 & ONC-002
ONC-001 & ONC-002 Reqorsa® Monotherapy & Reqorsa® + Tarceva Combination DOSE ESCALATION STUDY (ONC-001) REQORSA + TARCEVA (ONC-002) Favorable safety profile after being treated Ph 2 data in subjects with or without EGFR mutations in more than 50 patients. PRIOR BEST OVERALL EGFR MUTATION PRIOR NUMBE